Articles tagged with Lung Cancer
Researchers at Moffitt Cancer Center have identified IKBKE kinase as a potential targeted therapy for patients with tobacco-associated non-small cell lung cancer. The study suggests that IKBKE overexpression is induced by tobacco smoke and can be targeted to reduce cancer progression.
European women are at risk of dying from lung cancer, which is expected to overtake breast cancer as the main cause of death. According to research, lung cancer deaths have increased by 7% since 2009, while breast cancer deaths have declined steadily.
This study found that SUVmax is a significant and clinically independent marker for progression-free survival in stage I non-small cell lung cancer (NSCLC) patients. The research included 95 medically inoperable patients who received stereotactic body radiation therapy (SBRT), with median overall survival of 25.3 months and progression...
A study found that 1 in 4 lung cancer patients in Andalusia did not receive the radiotherapy they needed, resulting in a 3,000-day loss of life. This underuse has negative consequences for patients, highlighting the need for improved radiotherapy protocols.
A new report from the American Cancer Society finds that cancer death rates are narrowing for African Americans, with nearly 200,000 deaths avoided since 1990. However, racial disparities remain for certain cancers, including colorectal and female breast cancer, highlighting the need for improved access to healthcare and screening.
Researchers discovered that long non-coding RNA MALAT1 regulates genes involved in metastasis, leading to impaired mobility and tumor growth. By silencing MALAT1, the team found reduced metastasis formation in mice, opening a promising approach for lung cancer treatment.
A University at Buffalo study found that indoor air pollution contributes significantly to lung cancer risk in Chinese women, despite low smoking rates. The research measured particulate matter levels inside homes and linked them to lung cancer incidence, highlighting the need for improved ventilation systems and public education.
A meta-analysis of large randomised trials found no significant increase in cancer risk among those taking daily folic acid for 5 years or less. The study provides reassurance about the safety of folic acid intake, particularly in countries where fortification is mandatory.
Female smokers have seen a significant rise in the risk of death from lung cancer and chronic obstructive lung disease (COLD) in recent years, with a 25.7 times higher risk than never-smokers. This increase is largely attributed to changing smoking patterns, where women now smoke more like men, starting earlier and consuming more cigar...
A recent study found that residents in a rural Chinese village near an e-waste recycling site are 1.6 times more likely to develop lung cancer than their peers in a heavily polluted city. The study, conducted by Oregon State University researchers, highlights the risks of toxic air pollution from e-waste incineration.
The American Cancer Society's annual report shows a 20% decrease in cancer mortality rates since 1991, with significant drops in lung, colorectal, breast, and prostate cancers. These declines are attributed to reductions in smoking and improvements in early detection and treatment.
A recent study found that lung cancer mortality rates are disproportionately high among blacks living in the most segregated counties in the US. The study suggests that addressing socioeconomic disparities and improving access to healthcare may be key to reducing these disparities.
Researchers compared the patterns of failure between stereotactic body radiotherapy (SBRT), lobectomy, and pneumonectomy for patients with stage I non-small-cell lung cancer. The results show comparable patterns of failure, but highlight the challenges in making such comparisons due to differences in patient and tumor-related factors.
A recent study by IASLC found that EGFR mutations do not serve as a prognostic factor in NSCLC patients. Instead, smoking status appears to be the most significant predictor of overall survival. The researchers also discovered that administering EGFR TKI can prolong survival after disease recurrence.
Researchers found cancers with EGFR exon 20 insertions have similar clinical characteristics to those with common mutations but a poorer prognosis. Median survival was 16 months for these patients, shorter than those with other mutations.
The American Cancer Society recommends low-dose computed tomography (CT) screening for patients aged 55-74 with a 30-pack-year smoking history. A thorough discussion of benefits, limitations, and risks is essential before screening. Screening can reduce lung cancer mortality in high-risk groups.
Researchers found that a virulent strain of H. pylori reduced the risk of deaths from stroke by 55% and lung cancer by 45%. The study, which analyzed data from nearly 10,000 individuals, also found no association between H. pylori positivity or cagA-positivity and all-cause mortality.
A study of 722 patients found that those taking beta-blockers for other conditions lived longer after receiving radiotherapy. The use of beta-blockers improved survival rates without disease spreading or recurring, but not locoregional progression-free survival.
A new study proposes a possible pathway to benefit from drugs for lung cancer prevention by identifying microRNA-34c as a surrogate endpoint. Changes in its expression six months after treatment correlate with benefit from the drug, potentially speeding up the pace of discovery and bringing new agents to market.
Researchers analyzed over 400 patient records to find that the proportion of early-stage lung cancer cases identified by CT scans increased by almost 50% during a recent 10-year period. However, only half of these cases would meet criteria for lung cancer screening under existing guidelines.
A recent study published in the Journal of Thoracic Oncology found that COPD is not an independent risk factor for lung cancer. Researchers associated COPD with lung cancer, but attributed this link to smoking and ascertainment bias, highlighting the need for lung cancer screenings when diagnosing COPD.
A recent study found immunohistochemistry to be a reliable and accurate method for detecting ALK rearrangement in non-small cell lung cancer. The technique outperformed fluorescence in situ hybridization, which is currently the standard but time-consuming method.
A new study validates the IASLC/ATS/ERS classification for lung adenocarcinomas among Japanese patients, revealing prognostic value in histologic subtypes. The classification identifies specific molecular markers, such as EGFR and KRAS mutations, associated with prognosis and treatment outcomes.
Recent advancements in lung cancer treatment focus on targeting specific genetic mutations, resulting in improved patient response rates (70-80%) compared to traditional chemotherapies. However, challenges remain in securing funding for clinical trials and staying ahead of the disease's rapid mutation rate.
A team of researchers has discovered that the cellular reprogramming gene SOX2 is directly regulated by the tumor suppressor CDKN1B(p27) gene, which is also associated with cancers such as lung and pituitary cancer. The study also highlights the potential role of adult stem cells in cancer.
Routine use of upper endoscopy for most GERD patients does not improve patient health and may lead to unnecessary interventions. Computer alerts in HIV care improve patient outcomes by notifying providers of adverse events or missed appointments, leading to better follow-up practices.
Researchers have found that targeting resistant lung cancer 'pockets' with focused radiation can prolong disease control in patients who initially respond to crizotinib or erlotinib. This approach showed significant benefits in patients whose cancers progressed in the brain, where the drugs are less effective.
Lung cancer researchers at St. Joseph's Hospital and Medical Center identified a gene involved in non-small cell lung cancer tumor growth, leading to potential new treatments that inhibit tumor growth. The study found that the Fn14 gene is elevated in NSCLC tumors and promotes migration and invasion.
Researchers at Thomas Jefferson University have developed a new real-time tracking technique that can better predict and track tumor motion during radiotherapy, sparing healthy tissue. The technique has shown to deliver higher levels of radiation to moving tumors while reducing dose to critical organs.
Researchers found that local ablative therapy and continuation of targeted drugs can prolong disease control by up to 6.2 months in patients with EGFR mutations or ALK rearrangements. The study's findings suggest a new approach to treating NSCLC after progression, particularly for patients with oligoprogressive disease.
A study published in the Journal of Thoracic Oncology found that denosumab was associated with significantly improved overall median survival in lung cancer patients, including those with non-small-cell lung cancer and small-cell lung cancer. The treatment also showed improved survival in patients with squamous cell carcinoma.
Researchers have successfully genotyped 344 NSCLC specimens with a median turnaround time of 31 days, enabling targeted therapy. This study's findings highlight the potential for large-scale genomic testing to transform lung cancer treatment.
A University of Cincinnati research team isolated and grew lung cancer stem cells in a preclinical model, offering a new avenue for investigating immunotherapy options that specifically target stem cells. This breakthrough could lead to the development of novel therapies targeting these cells and improving treatment outcomes.
A large-scale genome-wide association study found three genetic regions associated with lung cancer risk in Asian female never-smokers. The discovery provides evidence that common inherited genetic variants contribute to an increased risk of lung cancer among this population.
Researchers developed models from PLCO data to predict smoking status, finding that relapse and continued smoking are linked to demographic and tobacco-related characteristics. The models suggest variables like longer-term smokers, recent quitters, and pipe or cigar smokers are at higher risk for relapse.
A study of 1.3 million women found that quitting smoking can significantly reduce the risk of premature death, with smokers who stop before age 30 avoiding nearly all excess risk. The risks associated with smoking are substantial and increase with the amount smoked, highlighting the importance of quitting to extend life.
Patients undergoing non-small cell lung cancer (NSCLC) resection who take statins may experience improved overall survival and reduced risk of recurrence. Statin use was associated with a significantly lower local recurrence rate compared to non-statin users.
Researchers found that JHQG significantly prolonged survival in patients with non-small cell lung cancer (NSCLC), improved quality of life and activity capacity in IPF patients, and reduced fever in influenza patients compared to standard care and placebo.
A long-term study found that radiotherapy after surgery significantly improves biochemical progression-free survival and local control for high-risk prostate cancer patients. However, its effects on clinical progression-free survival and overall survival are less clear.
A study published in the Journal of Thoracic Oncology found that fit elderly patients with non-small cell lung cancer can benefit from salvage targeted therapy without increased toxicity. The study analyzed data from 255 patients and showed no difference in response rates or progression-free survival between age groups.
Scientists at the University of York have discovered a protein called Ciz1 that is present in lung cancers, even in early stages. A simple blood test using this protein could help diagnose lung cancer without invasive procedures.
A study analyzing the International Mesothelioma Interest Group (IMIG) staging system for malignant pleural mesothelioma (MPM) reveals areas for potential revision. The current system distinguishes among T and N categories, but qualitative T descriptors may not be applicable to clinical staging.
A study published in the Journal of Thoracic Oncology found that VeriStrat can predict response to erlotinib, but does not provide a survival benefit. The test showed a significant difference in median survival between good and poor responders, with good responders experiencing longer survival on erlotinib.
A variant in the NFKB1 gene has been associated with a 44% reduced risk of lung cancer, according to a new analysis of 378 patients and 450 healthy controls. The study suggests that inflammation may play a role in lung cancer development.
Several new first-in-human studies for drugs targeting a range of cancers have shown promising results, including the development of MEK-, MET- and HSP90 inhibitors as well as immunotherapeutic strategies. Studies have demonstrated significant activity in ALK-positive lung cancer resistant to crizotinib and other targeted therapies.
A phase III trial shows that crizotinib is more effective than standard chemotherapy in response rates and progression-free survival, with improved quality of life. The study compared 347 patients with previously treated ALK-positive lung cancer and found significant benefits for those on the crizotinib arm.
A post-hoc analysis of the phase III MISSION trial suggests that patients with EGFR-mutant tumors may benefit from sorafenib, which showed improved progression-free survival and disease control rates. In contrast, median overall survival was similar between treatment groups.
A blood test developed by Kansas State University researchers can accurately detect the beginning stages of breast and non-small cell lung cancer. The test works by detecting increased enzyme activity in the body, with a 95% success rate in detecting cancer in participants.
Researchers found that genetic diversity in natural killer cells contributes to lung cancer susceptibility. In mice, manipulating the immune system can significantly block tumor growth. The study suggests a key role for natural killer cells in lung cancer, potentially offering new targets for therapy.
Recent breast cancer research at ESMO 2012 emphasizes the importance of avoiding weight gain after treatment to reduce recurrence risk. Additionally, studies focus on the correlation between body mass index and prognosis, as well as lung cancer in never-smoking women, highlighting hormonal factors and high incidence of EGFR mutation.
A pilot study found that breath testing can accurately discriminate between benign and malignant pulmonary nodules. The technique, using volatile organic compounds and chemical nanoarrays, identified 53 malignant and 19 benign nodules with high accuracy.
Two new studies have identified novel genes and patterns of mutations involved in lung cancer, with significant differences found between smokers and non-smokers. These findings could lead to targeted therapies to improve survival rates and outcomes for lung cancer patients.
Researchers found that standard chemotherapy with paclitaxel, carboplatin, and bevacizumab is equally effective as an experimental regimen in treating advanced non-squamous non-small cell lung cancer. The study suggests that both regimens are tolerable but have different toxicities.
A study of 14,829 Hispanic lung cancer patients from the California Cancer Registry found that foreign-born Hispanics have an even lower risk of death due to improved socio-economic factors and neighborhood conditions. This contradicts the traditional 'Hispanic paradox' by highlighting the positive impact of social factors on survival.
A recent study published in the University of Maryland Medical Center found that married lung cancer patients have a higher survival rate compared to single patients. The researchers believe that social support from spouses is a key factor contributing to improved survival rates for married lung cancer patients.
Crizotinib successfully shrinks tumors in patients with anaplastic lymphoma receptor tyrosine kinase (ALK) positive non-small cell lung cancer. The treatment showed a high overall response rate of 60% and improved median progression-free survival.
Patients with stage I non-small cell lung cancer (NSCLC) who received radiation therapy had an increased median survival of 21 months compared to 16 months. The percentage of patients not receiving treatment declined from 20 percent to 16 percent between 1999-2003 and 2004-2008.
Researchers found that adding bavituximab to docetaxel chemotherapy improves response rates, progression-free survival, and overall survival in late-stage non-squamous, non-small cell lung cancer (NS-NSCLC) patients. The study showed a doubling of the overall response rate compared to the control arm.
A study of 168 Stage III NSCLC patients found that married women had the best three-year survival rate of 46 percent, while single men had the worst rate of 3 percent. Married patients generally had improved survival rates compared to single patients, with 33 percent vs. 10 percent.
The study found an increase in non-smokers developing lung cancer, particularly women, and a shift towards adenocarcinoma. Researchers attributed this change to improved diagnostic techniques and management of lung cancer.